Rosiglitazone metformin adduct inhibits hepatocellular carcinoma proliferation via activation of AMPK/p21 pathway

BACKGROUND: Rosiglitazone metformin adduct (RZM) is a novel compound, synthesized from rosiglitazone (Ros) and metformin (Met) combined at a molar mass ratio of 1:1. Met and Ros are widely used together for treating type 2 diabetes to improve drug effectiveness and reduce adverse drug reactions. Rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yuyang, Hu, Xiangnan, Shan, Xuefeng, Chen, Ke, Tang, Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330460/
https://www.ncbi.nlm.nih.gov/pubmed/30651718
http://dx.doi.org/10.1186/s12935-019-0732-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330460/
https://www.ncbi.nlm.nih.gov/pubmed/30651718
http://dx.doi.org/10.1186/s12935-019-0732-2

Ejemplares similares